Publications

Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile.

Tuloup V, France M, Garreau R, Bleyzac N, Bourguignon L, Tod M, Goutelle S.

Antimicrob Agents Chemother. 2021 Aug 17

PubMed PMID: 34228545

Does DDI-Predictor Help Pharmacists to Detect Drug-Drug Interactions and Resolve Medication Issues More Effectively?

Moreau F, Simon N, Walther J, Dambrine M, Kosmalski G, Genay S, Perez M, Lecoutre D, Belaiche S, Rousselière C, Tod M, Décaudin B, Odou P.

Metabolites 2021 Mar 17;11(3):173.

PubMed PMID: 33802983

Drug interactions between the emergency contraception drugs and cytochrome inducers: literature review and quantitative prediction.

Le Corvaisier C, Capelle A, France M, Bourguignon L, Tod M, Goutelle S.

Fundam Clin Pharmacol. 2020 Aug 19

PubMed PMID: 32813881

Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8.

Tod M, Bourguignon L, Bleyzac N, Goutelle S.

Clin Pharmacokinet. 2019 Dec 16.

PubMed PMID: 31840223

A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.

Tod M, Goutelle S, Bleyzac N, Bourguignon L.

Clin Pharmacokinet. 2018 Sep 8;58(4):503-523.

PubMed PMID: 30194612

Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model.

Fermier N, Bourguignon L, Goutelle S, Bleyzac N, Tod M.

Clin Pharmacokinet. 2018 Dec;57(12):1581-1591

PubMed PMID: 29572664

Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism

Cerruti L, Bleyzac N, Tod M.

Clin Pharmacokinet. 2018 Jul;57(7):831-841

PubMed PMID: 28889370

Mechanisms of drug-drug interaction between rifampicin and fusidic acid.

Bel F, Bourguignon L, Tod M, Ferry T, Goutelle S.

Br J Clin Pharmacol. 2017 Aug;83(8):1862-1864.

PubMed Central PMCID: PMC5510078

Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it worth?

Tod M, Goutelle S, Bourguignon L, Bleyzac N.

CPT Pharmacometrics Syst Pharmacol. 2017; Apr;6(4):226.

PubMed PMCID: PMC5397559

A model for predicting the interindividual variability of drug-drug interactions.

Tod M, Bourguignon L, Bleyzac N, Goutelle S.

The AAPS Journal. 2017; Mar;19(2):497-509.

PubMed PMID: 27924615

Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.

Gabriel L, Tod M, Goutelle S.

Clin Pharmacokinetics 2016 Aug;55(8):977-90.

PubMed PMID: 26936044

Comparison of the static in vivo approach to a physiologically based pharmacokinetic approach for metabolic drug–drug interactions prediction.

Tod M, Pierrillas PB, Bourguignon L, Goutelle S.

Int J Pharmacokinetics Posted online on 4 Apr 2016

Link

A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.

Steelandt J, Jean-Bart E, Goutelle S, Tod M.

Clinical Pharmacokinetics 2015 Dec;54(12):1245-58.

PubMed PMID: 26070946

Pharmacokinetic drug interaction between cyclosporine and imatinib in bone marrow transplant children and model-based reappraisal of imatinib drug interaction profile.

Bleyzac N, Kebaili K, Mialou V, Bertrand Y, Goutelle S.

Ther Drug Monit. 2014 Dec;36(6):724-9.

PubMed PMID: 24739665

Reliability and Extension of Quantitative Prediction of CYP3A4-Mediated Drug Interactions Based on Clinical Data.

Loue C, Tod M.

AAPS Journal 2014 Nov;16(6):1309-20.

PubMed PMID: 25274605

In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates.

Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, Tod M

AAPS Journal 2013 Apr;15(2):415-26.

PubMed PMID: 23319287

Quantitative Prediction of the Impact of Drug Interactions and Genetic Polymorphisms on Cytochrome P450 2C9 Substrate Exposure.

Castellan AC, Tod M, Gueyffier F, Audars M, Cambriels F, Kassaï B, Nony P

Clinical Pharmacokinetics 2013 Mar;52(3):199-209.

PubMed PMID: 23344982

Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.

Tod M, Nkoud-Mongo C, Gueyffier F.

AAPS Journal 2013;15(4):1242-52

PubMed Central PMCID: PMC3787231

Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions.

Tod M, Goutelle S, Clavel-Grabit F, Nicolas G, Charpiat B.

Clinical Pharmacokinetics 2011 Aug;50(8):519-30.

PubMed PMID: 21740075

Genotype-based quantitative prediction of drug exposure for drugs metabolized by CYP2D6.

Tod M, Goutelle S, Gagnieu MC.

Clinical Pharmacology And Therapeutics 2011 Oct;90(4):582-7.

PubMed PMID: 21866098

General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.

Ohno Y, Hisaka A, Ueno M, Suzuki H.

Clinical Pharmacokinetics 2008;47(10):669-80.

PubMed PMID: 18783297

General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.

Ohno Y, Hisaka A, Suzuki H.

Clinical Pharmacokinetics. 2007;46(8):681-96.

PubMed PMID: 17655375